NCT01502085 2026-04-03
RZD
Hackensack Meridian Health
Phase 1/2 Completed
Clinical Trials
178 trialsNCT01242267 2026-04-02
Thal/Mel/Vel
Hackensack Meridian Health
Phase 1/2 Completed
NCT03441958 2026-03-18
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Ciusss de L'Est de l'Île de Montréal
Phase 1/2 Completed
NCT01615029 2026-03-16
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT01665794 2025-12-22
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
Phase 1/2 Completed
NCT02362035 2025-12-11
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT02328014 2025-12-09
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
Phase 1/2 Completed
NCT02937571 2025-11-20
High Dose Carfilzomib for Newly Diagnosed Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01592370 2025-10-22
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT07102706 2025-08-05
Phase I Trial of GR1803 Injection in Patients With RRMM
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT03548207 2025-07-30
CARTITUDE-1
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT06055075 2025-07-14
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed
NCT00112827 2025-06-06
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT04083534 2025-05-30
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Phase 1/2 Completed
NCT03417284 2025-05-01
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02649790 2025-03-19
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
Phase 1/2 Completed
NCT03544281 2025-03-18
DREAMM 6
GlaxoSmithKline
Phase 1/2 Completed
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT03773107 2025-01-13
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Completed
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT01857115 2024-11-13
wCCyd
European Myeloma Network B.V.
Phase 1/2 Completed
NCT01755975 2024-11-07
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
NCT02633059 2024-09-19
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT03267888 2024-09-04
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Emory University
Phase 1/2 Completed
NCT01183949 2024-08-02
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT03194867 2024-06-14
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Sanofi
Phase 1/2 Completed
NCT03430011 2024-05-24
EVOLVE
Juno Therapeutics, a Subsidiary of Celgene
Phase 1/2 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT03848845 2024-04-09
DREAMM 4
GlaxoSmithKline
Phase 1/2 Completed
NCT02812706 2024-04-01
Islands
Sanofi
Phase 1/2 Completed
NCT02119468 2024-03-15
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT02056756 2024-02-20
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
European Myeloma Network B.V.
Phase 1/2 Completed
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT02509052 2023-10-10
Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT02685826 2023-10-06
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
Celgene
Phase 1/2 Completed
NCT04445701 2023-08-22
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Arch Oncology
Phase 1/2 Completed
NCT02185820 2023-07-03
CPD
European Myeloma Network B.V.
Phase 1/2 Completed
NCT02204241 2023-07-03
CCD
European Myeloma Network B.V.
Phase 1/2 Completed
NCT01166113 2023-06-29
PCP
Fondazione EMN Italy Onlus
Phase 1/2 Completed
NCT01348919 2023-06-28
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00566098 2023-05-26
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02751255 2023-04-28
DARA/ATRA
Amsterdam UMC, location VUmc
Phase 1/2 Completed
NCT01794520 2023-04-10
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1/2 Completed
NCT01040026 2023-04-04
Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
University Hospital, Basel, Switzerland
Phase 1/2 Completed
NCT03312530 2023-02-28
A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed
NCT03439280 2023-02-24
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Takeda
Phase 1/2 Completed
NCT02186834 2023-01-04
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed